Role of genetic polymorphisms on neuroplasticity pathways in a cohort of Portuguese patients with Major Depressive Disorder

Growing evidence suggests the implication of brain plasticity in antidepressant drug (AD) efficacy. Several authors have been pointing out the role of the BDNF-TrkB signaling pathway, including the downstream kinases Akt and ERK, and the mTOR pathway in neuroplasticity [1-3]. Furthermore, the prediction of AD response phenotypes of depressed patients treated with AD drugs remains a challenge for clinicians. Although previous studies have suggested that genetic variants may play a key role in the mechanism of Treatment Resistance Depression and Relapse, attempts to identify risk polymorphisms within genes with putative interest in AD response, had a limited success.

URI

http://hdl.handle.net/10400.22/21698

Citation

Santos, M., Carvalho, S., Lima, L., Mota-Pereira, J., Pimentel, P., Correia, D., Maia, D., Gomes, S., Cruz, A., & Medeiros, R. (2022). Role of genetic polymorphisms on neuroplasticity pathways in a cohort of Portuguese patients with Major Depressive Disorder. Abstracts of the 35th ECNP Congress 2022, 1, 100975. https://doi.org/10.1016/j.nsa.2022.100975